Linked Life Data

7015693

Source:http://linkedlifedata.com/resource/pubmed/id/7015693

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1981-7-20
pubmed:abstractText
A coordinated clinical trial (phase II) of preparation VM-26 supplied by Sandos (Switzerland) was carried out at 5 clinics in a total of 61 patients with lymphoma. Two regimens of VM-26 administration were employed: (1) 5-day courses of 30 mg/m2 iv with 7-14 day intervals, or (2) two injections of 50 mg/m2 a week, within 4-6 weeks, depending on drug tolerance Out of 15 children with Hodgkin's disease, 50% of cases showed complete or partial remission. Out of 27 adults with Hodgkin's disease, response was registered in 69.9 and a pronounced effect--in 1 26.1%. Out of 14 patients with lymphosarcomas, response was observed in 78.5 and a pronounced effect--in 57.2%. Toxic effect was not the cause of treatment suspension in most cases.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0507-3758
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
82-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
[Use of preparation VM 26 (epipodophyllotoxin) for treating lymphomas in children and adults].
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract, Controlled Clinical Trial